India IP Policies Unlikely To Change Until Local R&D Pipelines Mature – McKinsey
This article was originally published in PharmAsia News
Executive Summary
McKinsey singles out clinical trial policies as the top obstacle to Indian innovation, but also takes a closer look at IP issues that could be holding the country back.